API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. F /
  3. 9SO.F

Solasia Pharma K.K (9SO F) stock market data APIs

€0.248 0(0%) as of October 31, 2024
Price chart is built with Anychart

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. The company was founded in 2006 and is based in Tokyo, Japan.

Solasia Pharma K.K Financial Data Overview

0.246
0.248
-
0.248
0.246
0.13-0.418
53 848 K
218 M
160 M
1.368
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '9SO',
Type: 'Common Stock',
Name: 'Solasia Pharma K.K',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'JP3436500007',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
}

Solasia Pharma K.K Fundamental Data is available in our Financial Data APIs

  • Net Revenue 160 M
  • EBITDA -912 000 000
  • Earnings Per Share -0.04
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Solasia Pharma K.K Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get Solasia Pharma K.K End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Solasia Pharma K.K latest news via APIs

Solasia Announces Launch of Darvias® in Japan

TOKYO, August 22, 2022--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that an organoa...
  • BUSINESS WIRE
  • SOLASIA PHARMA K.K
  • TOKYO
  • YOSHIHIRO ARAI

Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan

TOKYO, June 20, 2022--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that an organoarse...
  • MHLW
  • MITOCHONDRIAL FUNCTION
  • NIPPON KAYAKU
  • ORGANOARSENIC COMPOUND
  • PTCL
  • SOLASIA
  • SOLASIA PHARMA K.K
  • TOKYO
  • TREATMENT OPTIONS
  • TSE
  • YOSHIHIRO ARAI
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com